BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Anrikefon (HSK21542) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Anrikefon (HSK21542)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07380113-932@assetmemo.bio
DTSTAMP:20261121T005034Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Anrikefon (HSK21542): Phase 4 readout est. (NCT07380113)
DESCRIPTION:Anrikefon (HSK21542)\, phase 4\, Chronic Kidney Disease.\nStudy
 : Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With
  CKD-aP\nEstimated primary completion: 31 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/anrikefon-hsk21542#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07380113
URL:https://assetmemo.bio/drug/anrikefon-hsk21542#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
